Companies Provide Hormone Therapy Options for Women

|
Includes: BAYRY, NOVN-OLD, NVS, WCRX, WYE
by: H.S. Ayoub

In the Tuesday edition of the Wall Street Journal, Tara Parker-Pope wrote a great article detailing how the hormone patch is superior to the pill. She also listed the varying options women have for hormone replacement therapy with the associated risks and rewards.

Here is the information summarized, with the addition of the pharmaceutical and biotech companies involved:

PILLS
Pros: convenient, lower cholesterol and blood sugar
Cons: higher risk of blood clots

  • Permarin
    Wyeth (WYE)
  • Estrace
    Warner Chilcott (NASDAQ:WCRX)

  • PATCHES

    Pros: may lower clot risk, less side effects
    Cons: skin irritation, less likely to lower cholesterol

  • Climara
    Berlex, U.S. affiliate of Bayer (BAY)
  • Vivelle
    Novogyne Pharmaceuticals, a joint venture between Novartis (NYSE:NVS) and Noven (NOVN-OLD)

  • CREAMS/GELS

    Pros: may lower clot risk, easy application, less skin irritation
    Cons: messy

  • Estrogel
    Solvay Pharmaceuticals, U.S. division of Solvay S.A. [SOL.DE] of Belgium
  • Estrasorb
    Espirit Pharma
  • VAGINAL RING
    Pros: may lower clot risk
    Cons: can be uncomfortable

  • Femring
    Warner Chilcott [WCRX]
  • RELATED READING:
    - Public Awareness Needed Before Mandate to Vaccinate Girls with Merck's Gardasil
    - Expert Panel Urges Change to Birth Control Pill Studies

    About this article:

    Expand
    Want to share your opinion on this article? Add a comment.
    Disagree with this article? .
    To report a factual error in this article, click here